Improving how nanoparticles deliver cancer treatments using AI.
Computational Modeling on the Interaction of Nanomedicine with Protein Corona and Its Impact on Tumor Delivery Efficiency
This study is looking at how tiny particles used in cancer treatment can be improved with the help of artificial intelligence, making it easier to deliver medicine directly to tumors and potentially leading to safer and more effective treatments for cancer patients.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-11067863 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of cancer nanomedicine by using artificial intelligence to better understand how nanoparticles interact with proteins in the body. The goal is to create a computational model that predicts how well these nanoparticles can deliver therapeutic agents to tumors. By analyzing the protein corona that forms around nanoparticles, the research aims to optimize their delivery efficiency, potentially leading to safer and more effective cancer treatments. This approach could streamline the development process by reducing the number of nanoparticles that need to be tested in early-stage trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from advanced nanomedicine therapies.
Not a fit: Patients with non-solid tumors or those not eligible for nanomedicine treatments may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments through improved delivery of therapeutic agents.
How similar studies have performed: Other research has shown promise in using AI to enhance drug delivery systems, indicating that this approach could be effective.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Chou, Wei-Chun — University of California Riverside
- Study coordinator: Chou, Wei-Chun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.